Docoh
Loading...

SBBP Strongbridge Biopharma

Strongbridge Biopharma is a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs. Strongbridge's rare endocrine franchise includes RECORLEV® (levoketoconazole), a cortisol synthesis inhibitor currently being studied in Phase 3 clinical studies for the treatment of endogenous Cushing's syndrome, and veldoreotide extended release, a preclinical next-generation somatostatin analog being investigated for the treatment of acromegaly and potential additional applications in other conditions amenable to somatostatin receptor activation. Both RECORLEV and veldoreotide have received orphan drug designation from the FDA and the European Medicines Agency. The Company's rare neuromuscular franchise includes KEVEYIS® (dichlorphenamide), the first and only FDA-approved treatment for hyperkalemic, hypokalemic, and related variants of primary periodic paralysis. KEVEYIS has orphan drug exclusivity in the United States.

Company profile

Ticker
SBBP
Exchange
CEO
Matthew Pauls
Employees
Incorporated
Location
Fiscal year end
Former names
Cortendo AB
SEC CIK
Subsidiaries
Strongbridge U.S. Inc. • Strongbridge Dublin Limited • Cortendo AB ...

SBBP stock data

(
)

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

5 Aug 21
16 Oct 21
31 Dec 21
Quarter (USD)
Jun 21 Mar 21 Dec 20 Sep 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Dec 20 Dec 19 Dec 18 Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 63.77M 63.77M 63.77M 63.77M 63.77M 63.77M
Cash burn (monthly) 3.37M (positive/no burn) 4.41M 3.88M 3.28M 2.83M
Cash used (since last report) 11.99M n/a 15.68M 13.8M 11.64M 10.06M
Cash remaining 51.78M n/a 48.09M 49.97M 52.13M 53.71M
Runway (months of cash) 15.3 n/a 10.9 12.9 15.9 19.0

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
5 Oct 21 Steen Marten Ordinary Shares Sale back to company Dispose D Yes No 0 64,151 0 0
5 Oct 21 Steen Marten Stock Option Ordinary Shares Sale back to company Dispose D Yes No 0 154,918 0 0
5 Oct 21 Jeffrey W Sherman Ordinary Shares Sale back to company Dispose D No No 0 64,258 0 0
5 Oct 21 Jeffrey W Sherman Stock Option Ordinary Shares Sale back to company Dispose D No No 0 140,000 0 0
5 Oct 21 Kong Garheng Ordinary Shares Sale back to company Dispose D No No 0 63,993 0 0
5 Oct 21 Kong Garheng Stock Option Ordinary Shares Sale back to company Dispose D No No 0 154,385 0 0
5 Oct 21 Gill David N Ordinary Shares Sale back to company Dispose D No No 0 78,058 0 0
5 Oct 21 Stephen J Long Ordinary Shares Sale back to company Dispose D No No 0 117,793 0 0
5 Oct 21 Stephen J Long Stock Option Ordinary Shares Sale back to company Dispose D No No 0 714,045 0 0

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

57.6% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 61 75 -18.7%
Opened positions 19 10 +90.0%
Closed positions 33 7 +371.4%
Increased positions 12 25 -52.0%
Reduced positions 24 25 -4.0%
13F shares
Current Prev Q Change
Total value 121.5M 121.41M +0.1%
Total shares 39.09M 38.01M +2.8%
Total puts 43.5K 63.5K -31.5%
Total calls 36.2K 46K -21.3%
Total put/call ratio 1.2 1.4 -13.0%
Largest owners
Shares Value Change
Caxton 8.08M $24.01M 0.0%
NEA Management 4.14M $12.3M 0.0%
HealthCap VI 3.8M $9.24M 0.0%
Stonepine Capital Management 3.31M $9.82M +641.7%
Rubric Capital Management 2.7M $8.01M NEW
Vanguard 2.2M $6.53M -4.9%
MS Morgan Stanley 1.96M $5.81M -16.0%
Orbimed Advisors 1.74M $5.18M 0.0%
Tudor Investment Corp Et Al 1.53M $4.54M NEW
Renaissance Technologies 1.43M $4.24M -7.7%
Largest transactions
Shares Bought/sold Change
Stonepine Capital Management 3.31M +2.86M +641.7%
Rubric Capital Management 2.7M +2.7M NEW
AIGH Capital Management 0 -2.19M EXIT
BLK Blackrock 218.37K -1.98M -90.1%
Tudor Investment Corp Et Al 1.53M +1.53M NEW
Ikarian Capital 0 -1.16M EXIT
Ergoteles 1.1M +1.1M NEW
Hudson Bay Capital Management 0 -1.03M EXIT
MNGPF Man 983.32K +983.32K NEW
Millennium Management 638.03K +638.03K NEW
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. junior Avg
New words: automatically, banking, batch, Book, called, choose, combination, combined, consummate, consummation, correspondingly, CVR, decline, expire, fourth, gradual, iii, inestimable, joint, letter, listing, merger, metformin, official, Orange, outcome, PDUFA, pending, political, posed, promptly, proxy, recent, register, registration, reputational, requisite, resurgence, schedule, shareholder, solicit, track, unanimously, unchanged, User, USPTO, vaccine, worth
Removed: adversely, application, local, outbreak, suspended

Patents

APP
Utility
Methods and Compositions for Treating Diabetes, Metabolic Syndrome and Other Conditions
30 Sep 21
Pharmaceuticals compositions comprising the 2S, 4R, ketoconazole enantiomer or its pharmaceutically acceptable salts, hydrates, and solvates, that are substantially free of the 2R, 4S ketoconazole enantiomer are useful to reduce cortisol synthese and for the treatment of type 2 diabetes, hyperglycemia, obesity, insulin resistance, dyslipidemia, hyperlipidemia, hypertension, Metabolic Syndrome, and other diseases and conditions, including but not limited to Cushing's Syndrome, depression, and glaucoma.
APP
Utility
Compositions and Methods of Use
23 Sep 21
Provided is a pharmaceutical composition comprising: (a) granules comprising an active pharmaceutical ingredient, and one or more intragranular excipients; and an extragranular portion comprising at least one release modifier.
APP
Utility
Methods of Treating Disease with Levoketoconazole
2 Sep 21
Provided herein is a method of administering levoketoconazole, or a pharmaceutically acceptable salt thereof, to a subject in need thereof, wherein the subject is also being administered a multidrug and toxin extrusion transporter 1 (MATE1) substrate or an organic cation transporter 2 (OCT2) substrate.
APP
Utility
Methods of Treating Disease with Dichlorphenamide
22 Jul 21
Provided herein is a method for administering dichlorphenamide, or a pharmaceutically acceptable salt thereof, to a subject in need thereof, wherein the subject is also being administered a therapeutically effective amount of a drug chosen from a P-gp substrate, BCRP substrate, OAT2 substrate, OAT4 substrate, OCT1 substrate, MATE1 substrate, MATE2-K substrate, and combinations thereof.
GRANT
Utility
Methods of treating disease with levoketoconazole
1 Jun 21
Provided herein is a method of administering levoketoconazole, or a pharmaceutically acceptable salt thereof, to a subject in need thereof, wherein the subject is also being administered a multidrug and toxin extrusion transporter 1 (MATE1) substrate or an organic cation transporter 2 (OCT2) substrate.